Trial Profile
A Phase 1 Dose Escalation Study of ARQ 197 Administered in Combination With Erlotinib in Adult Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Tivantinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors ArQule
- 11 Sep 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 11 Sep 2009 Additional lead investigators (Just RG, Rosen L) as reported by ClinicalTrials.gov.
- 11 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.